Krupp L B, Christodoulou C
Department of Neurology, State University of New York at Stony Brook, HSC-T12-020, Stony Brook, NY 11794-8121, USA.
Curr Neurol Neurosci Rep. 2001 May;1(3):294-8. doi: 10.1007/s11910-001-0033-7.
Fatigue is among the most common, yet least understood, symptoms of multiple sclerosis (MS) [1.]. It can profoundly disrupt the occupational and social functioning of patients, and is recognized as a criterion for MS disability by the Social Security Administration. Most approaches to fatigue assessment can be classified as either self-report scales or performance-based measures of motor or cognitive output. During the clinical management of fatigue, it is important to consider the role of other MS symptoms on fatigue, as well as that of non-MS-related medical conditions. Management of fatigue in MS often entails both pharmacologic and behavioral components. This article reviews recent developments in the assessment, treatment, and pathogenesis of MS fatigue.
疲劳是多发性硬化症(MS)最常见但却最不为人所理解的症状之一[1]。它会严重扰乱患者的职业和社交功能,并且被美国社会保障局认定为MS致残的一项标准。大多数疲劳评估方法可分为自我报告量表或基于运动或认知输出的表现性测量方法。在疲劳的临床管理中,重要的是要考虑其他MS症状对疲劳的作用,以及非MS相关医疗状况的作用。MS疲劳的管理通常需要药物和行为两方面的措施。本文综述了MS疲劳在评估、治疗和发病机制方面的最新进展。